ReviewCurrent pharmaceutical design2025
Nanoparticles as Novel Drug Delivery Systems for Cancer Treatment: Current Status and Future Perspectives.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Macrophage-Based Nanoplatforms for Tumor-Targeted Drug Delivery and Cancer Immunomodulation: Extracellular Vesicles, Membrane-Coated Nanoparticles, and Live Cells.International journal of nanomedicine · 2026Review
- Olink Proteomics in Heart Failure: A Comprehensive Review of Applications From Biomarker Discovery to Pathophysiological Insights and Clinical Implementation.Reviews in cardiovascular medicine · 2026Review
- Regulatory Signaling Pathways in Ovarian Cancer Stem Cells: Their Role in Tumor Progression and Therapeutic Strategies.Iranian biomedical journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cancer continues to pose a significant global health challenge, demanding innovative therapeutic approaches to overcome the limitations of conventional treatments like chemotherapy and radiotherapy. Nanoparticles (NPs) have emerged as promising tools for cancer therapy due to their unique physicochemical properties that enable targeted drug delivery, reduced systemic toxicity, and enhanced therapeutic efficacy. This comprehensive review delves into the mechanisms of NP-based drug delivery, highlighting both passive and active targeting strategies. It categorizes and discusses diverse NP types, including polymeric, lipid-based, and metallic nanoparticles, emphasizing their applications in enhancing the bioavailability and specificity of anticancer agents. This review also explores the integration of advanced technologies, such as theranostics and artificial intelligence, to optimize NP design and functionality for personalized medicine. However, challenges remain, including issues related to toxicity, drug resistance, and manufacturing scalability. Addressing these barriers requires interdisciplinary research focused on developing stimuli-responsive NPs, improving biocompatibility, and incorporating multimodal therapeutic platforms. Although substantial progress has been made, this review is limited by the paucity of clinical trials validating NP efficacy and safety in diverse patient populations. Future endeavors should prioritize translational research to bridge the gap between preclinical innovations and clinical applications, ensuring that these transformative technologies benefit a broader spectrum of cancer patients. The review underscores the immense potential of NPs in redefining cancer treatment while advocating for sustained research to address existing limitations and unlock their full therapeutic promise.
Indexed as
Identifiers
40247800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.